A partnership agreement has been signed by Op2Lysis with Inserm research unit U1237 and University of Caen. This academic laboratory is focused on stroke research, from research on pathophysiological mechanisms to the identification of innovative therapeutic options.
This partnership is the logical next step, as it follows research activities leaded in this research unit over more than 10 years by Jérôme Parcq, cofounder of Op2Lysis. The resulting share of human and technological assets will help moving forward O2L-001 development towards clinical stage, and will allow initiation of new research programs.
This cooperation established by Op2Lysis and Inserm and University of Caen will favor success in our fight against the severe consequences of hemorrhagic strokes
To know more, please click on the following:
Op2Lysis has obtained a M€ 0.5 grant, following the « Innov Avenir Entreprises » call for projects, which was lauched by the Government and by the Normandy Region as the third round of the Programme d’investissements d’avenir (PIA). This grant will fund almost 50% of the budget to set up a pilot for production and purification of O2L-001, including development of a stable cell line to express O2L-001, which is a key step in the development plan of our drug candidate to treat hemorrhagic stroke patients. This award reflects the increasing support from the Government (through the DIRRECTE), the Normandy Region and bpifrance (which appraised our application) to progress towards the preclinical regulatory development phase and submit a Clinical Trial Application Form in Europe and an IND in the US in the next two years.
The application of Op2Lysis was granted on last October. This membership will allow us to benefit from the network of France Biotech and will give us the opportunity to contribute as well.
Thierry Sempere, who was recently appointed as new President of WICAP Op2Lysis, the holding that represents all WiSEEDers who invested in Op2Lysis within the crowdfunding campaign for the first round of fundraising, will join the Strategic Committee of Op2Lysis for its next meeting, in replacement of Alexis Nogues. The professional background of Thierry in the pharmaceutical industry, which includes a sound international operational experience, will bring a strong contribution to the Strategic Committee, in complementarity with other members.
We welcome Thierry in this new assignment, and we thank Alexis for his contribution to our project.
The 6 members of the Strategic Committe of Op2Lysis are now the following persons : Patrick Cassagne, Christophe Gaudin, Philippe Monteyne, Jean-Claude Muller, Jérôme Parcq et Thierry Sempere.
Efficient Innovation was selected to perform a qualitative market research, which will help us to enhance our understanding of market expectation about our product and to reinforce the most critical characteristics of our target product profile.
This work will be funded in part by the competitive cluster Medicen Paris Region in a three-way contract, with a joint participation of Conseil Régional d’Ile de France and European Union Feder funds.
Marie-Julie Guichard joined us on last 29 October 2018. She will be in charge of translational and regulatory studies.
Marie-Julie is a PhD from the University of Louvain in Belgium where she worked on the preclinical development of a drug treatment for cystic fibrosis patients. During her training period, she also benefited from a US research experience in a biotech company in Cambridge, MA.
Op2Lysis has been selected to join Neighborhood, a life science innovation center developed by Voisin Consulting Life Sciences that supports health tech startups in providing strategic and development regulatory coaching to favor growth. Marie-Julie will be working at Neighborhood office space and will benefit from a regulatory mentoring adapted to her new responsibilities
Last October 29th was also the World Stroke Day, which is a very good sign. We wish Marie-Julie every success in her new assignment, which is a key role for Op2Lysis preclinical development progress.
E.L : I am Project Engineer at Op2Lysis. I am also a PhD student, within a collaborative industrial agreement between Op2Lysis and Inserm research unit U1237.
I obtained a Bachelor at the University of Fribourg and a Master in medical biology, with a specialization in neuroscience, at the University of Zurich. I obtained all my degrees in Switzerland, which is the country where I was born
E.L : I was very pleased to join the Op2lysis team. First, because I think that the project is very interesting, both from the scientific and the human perspectives. I am proud to be a part of this project. I always wanted to work for a company that is at the edge of technology and that uses this science to serve the public health care. Additionally, I benefit from the opportunity of strengthening my professional experience and skills beyond my academic training, through this private-public combination.
E.L : Our technology is based on perfect knowledge of stroke mechanisms as well as tPA mechanisms of action, which will allow best use of our drug candidate in patients with an intracerebral hemorrhage.
Our product is specifically designed to treat patients with intracerebral hemorrhage easily and with best safety.
E.L : As a Project Engineer at Op2Lysis, my responsibility is to conduct the scientific experiments which are required to allow further development of our technology. Therefore, I use daily my scientific skills and technical knowledge, as well as the analytic capacity that I acquired all along my training.
I can participate in some decisions about company communication. I would like to be able to bring new perspectives for the company through my PhD project.
Op2Lysis has obtained the Innovative Young Company label from the French Ministry of Higher Education and Research. Together with CIFRE contract, this label is the second key support received by Op2Lysis over these last few weeks to strengthen its innovation.
Op2Lysis has been ranked as the 7th best start up (out of the initially 100 companies selected at the beginning of the competition) at the Big Booster Demo Days 2018, in Lyon (France) and is now a member of the 2018 Big Booster Class. This success offers the opportunity to fly to Boston and to Shanghai in the next few months in order to consolidate existing partnerships and to open new opportunities for business with the USA and China.
More information on Big Booster: http://www.bigbooster.org/index.php